Vaccinex Past Earnings Performance
Past criteria checks 0/6
Vaccinex has been growing earnings at an average annual rate of 11.2%, while the Biotechs industry saw earnings growing at 12.7% annually. Revenues have been declining at an average rate of 2.6% per year.
Key information
11.2%
Earnings growth rate
51.2%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | -2.6% |
| Return on equity | n/a |
| Net Margin | -3,552.8% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Revenue & Expenses BreakdownBeta
How Vaccinex makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 1 | -20 | 7 | 0 |
| 30 Sep 23 | 1 | -22 | 7 | 3 |
| 30 Jun 23 | 1 | -22 | 7 | 0 |
| 31 Mar 23 | 1 | -20 | 6 | 0 |
| 31 Dec 22 | 0 | -20 | 6 | 0 |
| 30 Sep 22 | 0 | -19 | 6 | 10 |
| 30 Jun 22 | 0 | -20 | 6 | 0 |
| 31 Mar 22 | 0 | -20 | 6 | 0 |
| 31 Dec 21 | 1 | -22 | 6 | 0 |
| 30 Sep 21 | 1 | -24 | 7 | -17 |
| 30 Jun 21 | 1 | -28 | 7 | 0 |
| 31 Mar 21 | 1 | -28 | 7 | 0 |
| 31 Dec 20 | 1 | -29 | 7 | 0 |
| 30 Sep 20 | 1 | -29 | 7 | 17 |
| 30 Jun 20 | 0 | -28 | 7 | 0 |
| 31 Mar 20 | 0 | -30 | 7 | -7 |
| 31 Dec 19 | 1 | -32 | 7 | 0 |
| 30 Sep 19 | 1 | -34 | 6 | 7 |
| 30 Jun 19 | 1 | -33 | 6 | 12 |
| 31 Mar 19 | 1 | -31 | 5 | 25 |
| 31 Dec 18 | 1 | -30 | 5 | 22 |
| 30 Sep 18 | 1 | -24 | 4 | 20 |
| 30 Jun 18 | 0 | -24 | 4 | 19 |
| 31 Mar 18 | 0 | -23 | 5 | 17 |
| 31 Dec 17 | 0 | -22 | 4 | 17 |
| 31 Dec 16 | 0 | -26 | 4 | 16 |
Quality Earnings: VCNX is currently unprofitable.
Growing Profit Margin: VCNX is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: VCNX is unprofitable, but has reduced losses over the past 5 years at a rate of 11.2% per year.
Accelerating Growth: Unable to compare VCNX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: VCNX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-8.9%).
Return on Equity
High ROE: VCNX's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.